Biogen Inc. (BIIB) insider have most recently took part in a trading activity. On Nov 29, 2017 Denner Alexander J, Director bought 30,000 shares having total worth of $9,520,800 at the price of $317.36 per share, following the transaction a total of 423,887 shares owned by Denner Alexander J. Before this latest buy, Denner Alexander J purchased BIIB at 1 other times during the past twelve months, for a total investment of $205.7M at an average of $278.5 per share.
Furthermore, over the past 12 months , the stock was traded 12 times by insiders. In 9 of these trades, the insider was a seller while an employee of the company was the buyer in 3 instances.
Shares of Biogen Inc. (BIIB) traded up 0.89% on Nov 29, 2017, hitting $319.96. 1,266,950 shares of the company’s stock traded hands. Biogen Inc. has a 52 week low of $224.6 and a 52 week high of $344.58. The company’s market cap is $68,920 million.
Biogen Inc. (BIIB) last announced its earnings results on Oct 25, 2017. The company reported 0.00 earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company posted 5.19 earnings per share. The company’s revenue for the quarter was down 100% on a year-over-year basis.
|earnings per share||0.00||6.31||5.04||5.20||5.04||5.19||5.21||4.79||4.50||4.48|
Biogen Inc. has been the subject of a number of recent research reports. Analysts at Morgan Stanley Maintains shares of Biogen Inc. to an Equal-Weight rating in a research note. They now have a $301.00 price target on the stock.
Biogen Idec Inc., was formed as a California corporation in 1985 and became a Delaware corporation in 1997. In 2003, the Company acquired Biogen, Inc. and changed its corporate name from IDEC Pharmaceuticals Corporation to Biogen Idec Inc. The Company is a global biotechnology company that discovers, develops, manufactures and markets therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. The Company also collaborates on the development and commercialization of RITUXAN and anti-CD20 product candidates for the treatment of non-Hodgkin’s lymphoma and other conditions. The Company’s marketed products include AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. AVONEX is one of the prescribed treatments in the world for relapsing forms of MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. TYSABRI has advanced the treatment of MS patients with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn’s disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin’s lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. FUMADERM is approved for the treatment of severe psoriasis in Germany. Psoriasis is a skin disease in which cells build up on the skin surface and form scales and red patches. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care ‘fraud and abuse,’ including anti-kickback laws and false claims laws.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018